269. 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群 Pyogenic arthritis Clinical trials / Disease details

臨床試験数 : 24 / 薬物数 : 30 - (DrugBank : 12) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 105

diseases per page:

Showing 1 to 10 of 24 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04901325 (ClinicalTrials.gov)	September 29, 2021	17/5/2021	Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)	Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)	Pyoderma Gangrenosum;Skin Diseases;Wound Heal;Pyoderma;Skin Ulcer	Drug: Baricitinib	Oregon Health and Science University	NULL	Recruiting	18 Years	99 Years	All	20	Phase 2	United States
2	NCT05120726 (ClinicalTrials.gov)	June 2, 2021	11/9/2021	A Novel Therapeutic Treatment of Pyoderma Gangrenosum	A Novel Therapeutic Treatment of Pyoderma Gangrenosum	Pyoderma Gangrenosum	Biological: Dehydrated human amnion/chorion membrane	Louisiana State University Health Sciences Center in New Orleans	NULL	Recruiting	18 Years	N/A	All	20	Phase 4	United States
3	NCT04895566 (ClinicalTrials.gov)	May 24, 2021	17/5/2021	Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderm ...	Phase 0/1 Topical Application of the Monoclonal Antibody (Mab) sB24M in Patients With Severe Pyoderm ...	Pyoderma;Pyoderma Gangrenosum;Pyoderma Vegetans;Pyoderma Gangrenosum Surrounding Surgical Stoma	Biological: Monoclonal antibody (Mab) sB24M	SWISS BIOPHARMA MED GmbH	NULL	Active, not recruiting	21 Years	80 Years	All	10	Early Phase 1	Belarus;Latvia
4	NCT04274166 (ClinicalTrials.gov)	May 2021	12/2/2020	Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum	The Efficacy and Safety of Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum	Pyoderma Gangrenosum	Drug: secukinumab 150 mg (2 injections per dose	Wake Forest University Health Sciences	Novartis	Withdrawn	18 Years	75 Years	All	0	Phase 2	United States
5	EUCTR2020-003273-21-PL (EUCTR)	09/11/2020	08/09/2020	NA	Open label exploratory phase IIa trial to investigate the safety and efficacy of IFX-1 in treating s ...	Pyoderma gangrenosum MedDRA version: 20.0;Level: PT;Classification code 10037635;Term: Pyoderma gang ...	Product Name: IFX-1 Other descriptive name: Anti-(complement C5a) IgG4 chimeric monoclonal antibody Pr ...	InflaRx GmbH	NULL	Not Recruiting			Female: yes Male: yes	18	Phase 2	United States;Poland
6	NCT03971643 (ClinicalTrials.gov)	May 16, 2019	28/5/2019	Exploratory Study of IFX-1 in Subjects With Pyoderma Gangrenosum	Open Label Exploratory Phase 2a Trial to Investigate the Safety and Efficacy of IFX-1 in Treating Su ...	Pyoderma Gangrenosum	Drug: IFX-1	InflaRx GmbH	Innovaderm Research Inc.	Completed	18 Years	N/A	All	19	Phase 2	United States;Canada;Poland
7	NCT03311464 (ClinicalTrials.gov)	October 27, 2017	12/10/2017	A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosumin ...	A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Acti ...	Pyoderma Gangrenosum	Drug: adalimumab	AbbVie	NULL	Completed	18 Years	N/A	All	22	Phase 3	Japan
8	NCT03072953 (ClinicalTrials.gov)	June 7, 2017	17/2/2017	Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum	A Phase 2a, Open-label, Proof of Concept Study to Determine the Efficacy and Safety of Etrasimod (AP ...	Pyoderma Gangrenosum	Drug: APD334	Arena Pharmaceuticals	NULL	Terminated	18 Years	80 Years	All	2	Phase 2	Australia;New Zealand
9	NCT03137160 (ClinicalTrials.gov)	May 4, 2017	27/4/2017	An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum	An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum	Pyoderma Gangrenosum	Biological: Ixekizumab	Ohio State University	Eli Lilly and Company	Completed	18 Years	N/A	All	5	Phase 2	United States
10	NCT02733094 (ClinicalTrials.gov)	April 2016	28/3/2016	Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoder ...	Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoder ...	Pyoderma Gangrenosum	Drug: Secukinumab	Technische Universität München	Novartis	Active, not recruiting	18 Years	75 Years	All	8	Phase 1/Phase 2	Germany

First Previous1 2 3Next Last